Xencor Doses First Patient in Phase 1 Study of XmAb20717 Dual Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors Read more about Xencor Doses First Patient in Phase 1 Study of XmAb20717 Dual Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors
Xencor to Present at Upcoming Investor Conferences Read more about Xencor to Present at Upcoming Investor Conferences
Xencor Reports First Quarter 2018 Financial Results Read more about Xencor Reports First Quarter 2018 Financial Results
Xencor to Present at Deutsche Bank 43rd Annual Health Care Conference Read more about Xencor to Present at Deutsche Bank 43rd Annual Health Care Conference
Xencor to Host First Quarter 2018 Financial Results Webcast and Conference Call on May 7, 2018 Read more about Xencor to Host First Quarter 2018 Financial Results Webcast and Conference Call on May 7, 2018
Xencor Presents Preclinical Data on XmAb®24306, Introduces XmAb® IL15 Bispecific Platform at American Association for Cancer Research (AACR) 2018 Annual Meeting Read more about Xencor Presents Preclinical Data on XmAb®24306, Introduces XmAb® IL15 Bispecific Platform at American Association for Cancer Research (AACR) 2018 Annual Meeting
Xencor to Present at 17th Annual Needham Healthcare Conference Read more about Xencor to Present at 17th Annual Needham Healthcare Conference
Xencor Announces Pricing of Public Offering of Common Stock Read more about Xencor Announces Pricing of Public Offering of Common Stock
Xencor, Inc. Announces Proposed Public Offering of Common Stock Read more about Xencor, Inc. Announces Proposed Public Offering of Common Stock
